Holen Sie sich die Stockscreener-App
0.4354
7.12%
0.0153
Handel nachbörslich:
.43
-0.0054
-1.24%
Schlusskurs vom Vortag:
$0.4201
Offen:
$0.373
24-Stunden-Volumen:
746.36K
Relative Volume:
6.64
Marktkapitalisierung:
$1.55M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.35M
KGV:
-0.9465
EPS:
-0.46
Netto-Cashflow:
$-5.48M
1W Leistung:
-17.13%
1M Leistung:
-34.80%
6M Leistung:
-71.88%
1J Leistung:
+6.41%
1-Tages-Spanne:
$0.3601
$0.51
1-Wochen-Bereich:
$0.3601
$0.5878
52-Wochen-Spanne:
$0.2872
$3.30
Shuttle Pharmaceuticals Holdings Inc Stock (SHPH) Company Profile
Firmenname
Shuttle Pharmaceuticals Holdings Inc
Sektor
Telefon
(240) 403-4212
Adresse
401 PROFESSIONAL DRIVE, GAITHERSBURG
Vergleichen Sie SHPH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SHPH
Shuttle Pharmaceuticals Holdings Inc
|
0.4354 | 1.55M | 0 | -7.35M | -5.48M | -0.46 |
|
ZTS
Zoetis Inc
|
161.67 | 71.94B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.94 | 47.16B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.19 | 46.33B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.48 | 18.69B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.25 | 13.96B | 612.78M | -86.37M | -62.91M | -0.87 |
Shuttle Pharmaceuticals Holdings Inc Aktie (SHPH) Neueste Nachrichten
This Md. biotech wants to get a cancer treatment to patients. It just tapped an industry outsider as co-CEO. - The Business Journals
Shuttle Pharma announces $5.75 million stock offering - Investing.com
Shuttle Pharma Secures Critical $5.75M Funding for Revolutionary Cancer Radiation Therapy - StockTitan
4 Artificial Intelligence (AI) Stocks Worth Buying in the Tech Sell-Off - The Globe and Mail
Lucid Group (LCID) Prepares to Sink Into Penny Stock Territory - The Globe and Mail
Shuttle Pharma appoints new interim co-CEO - Investing.com
Shuttle Pharmaceuticals appoints Christopher Cooper as interim Co-CEO - TipRanks
Shuttle Pharma Announces Appointment Of Christopher Cooper As Interim Co-CEO To Enhance Business Activities - Marketscreener.com
Shuttle Pharmaceuticals Appoints Christopher Cooper as Co-CEO - TipRanks
Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities - GlobeNewswire
Shuttle Pharma Strengthens Leadership: New Co-CEO to Accelerate Growth While Phase 2 Trial Advances - StockTitan
SHPH stock touches 52-week low at $0.5 amid sharp annual decline - Investing.com Australia
SHPH stock touches 52-week low at $0.5 amid sharp annual decline By Investing.com - Investing.com South Africa
Zscaler: Bullish Pressure Builds, Rapid Price Increase Expected - The Globe and Mail
Shuttle Pharmaceuticals Holdings Offers Up To 10,000,000 Shares Of Common Stock -March 05, 2025 at 07:42 am EST - Marketscreener.com
Amendment: SEC Form S-1/A filed by Shuttle Pharmaceuticals Holdings Inc. - Quantisnow
Shuttle Pharmaceuticals Enters Revolving Loan Agreement - TipRanks
Shuttle Pharmaceuticals Holdings Enters $2 Million Revolving Loan Agreement -February 28, 2025 at 05:26 pm EST - Marketscreener.com
Shuttle Pharmaceuticals Holdings Enters $2 Million Revolving Loan Agreement - TradingView
3 Reasons to Sell RH and 1 Stock to Buy Instead - The Globe and Mail
SEC Form 424B3 filed by Shuttle Pharmaceuticals Holdings Inc. - Quantisnow
Shuttle Pharmaceuticals Amends Agreement with Alto Fund By Investing.com - Investing.com Australia
Shuttle Pharmaceuticals Amends Agreement with Alto Fund - Investing.com
SHPH stock touches 52-week low at $0.57 amid market challenges By Investing.com - Investing.com South Africa
SHPH stock touches 52-week low at $0.57 amid market challenges - Investing.com
Shuttle Pharma advances glioblastoma trial, expands diagnostics - Investing.com India
Shuttle Pharma advances glioblastoma trial, expands diagnostics By Investing.com - Investing.com South Africa
Shuttle Pharmaceuticals Holdings, Inc. Reports Progress on Phase 2 Trial and Diagnostic Advancements in Annual Update - Nasdaq
Shuttle Pharma Provides Corporate Update and Reports 2024 Results - GlobeNewswire
Can Shuttle Pharma's Glioblastoma Treatment Breakthrough Deliver Returns? CEO Bets $237K - StockTitan
Shuttle Pharmaceuticals Holdings, Inc. SEC 10-K Report - TradingView
Why Five9 Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - Benzinga
Contrasting Shuttle Pharmaceuticals (NASDAQ:SHPH) and Insmed (NASDAQ:INSM) - Defense World
Form S-1 Shuttle Pharmaceuticals - StreetInsider.com
Here’s Why Shuttle Pharma is the Most Undervalued Biotech Stock in Our Coverage Universe - NewsBreak
Norwegian Air Shuttle ASA (NWARF) Expected to Announce Earnings on Thursday - Defense World
Badger Meter (BMI) Q4 Earnings Report Preview: What To Look For - The Globe and Mail
Shuttle Pharmaceuticals expands glioblastoma trial - MSN
Form 424B3 Shuttle Pharmaceuticals - StreetInsider.com
BlackRock MuniHoldings New York Quality Fund Enters Standstill Agreement with Saba Capital Management - Defense World
Cadre Holdings, Inc. (NYSE: CDRE) Enters Share Purchase Agreement with Carr’s Group PlcOn January 15, 2025, Cadre Holdings, Inc. (the “Company”) disclosed that it has entered into a Share Purchase Agreement with Carr’s Group Plc, selling all of the i - Defense World
GAN Limited Notifies of Non-Compliance with Nasdaq Listing RulesOn January 14, 2025, GAN Limited (NASDAQ: GAN) received a written notice from The Nasdaq Stock Market LLC stating that the company was not in compliance with Listing Rules 5620(a) a - Defense World
**Monster Beverage Corporation to Host Investor Meeting for Business Update**** - Defense World
Shuttle Pharmaceuticals Hits Milestone in Patient Enrollment for Phase 2 Clinical Trial - Defense World
Shuttle Pharma hits 25% mark in glioblastoma trial - MSN
Shuttle Pharma hits 25% mark in glioblastoma trial By Investing.com - Investing.com Australia
Shuttle Pharma Reaches Milestone in Patient Enrollment for - GlobeNewswire
Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma - Marketscreener.com
Shuttle Pharma Hits 25% Enrollment in Phase 2 Glioblastoma Trial for Promising Radiation Drug - StockTitan
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by Wealth Enhancement Advisory Services LLC - Defense World
Shuttle Pharmaceuticals (NASDAQ:SHPH) Faces Potential Delisting from Nasdaq due to Minimum Bid Price Requirement Noncompliance - Defense World
Finanzdaten der Shuttle Pharmaceuticals Holdings Inc-Aktie (SHPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.78%
2.54%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):